MiNK Therapeutics (INKT)
Develops allogeneic, off-the-shelf iNKT cell therapies for cancer and immune-mediated diseases.
Something off on this page? Send us feedback.
Develops allogeneic, off-the-shelf iNKT cell therapies for cancer and other immune-mediated diseases. Its single reportable segment centers on the clinical-stage agenT-797 program and an operating relationship with Agenus.
Develops allogeneic, off-the-shelf iNKT cell therapies for cancer and other immune-mediated diseases. Within a single reportable segment, it discovers, develops, and manufactures therapies, with agenT-797 its most advanced product candidate.
Formed as an Agenus subsidiary, it remains integrated with Agenus for finance, human resources, information technology, and legal functions. Its iNKT platform includes patent rights and know-how obtained through an Agenus intellectual-property assignment and license agreement.
The business depends on successful development and eventual marketing approval of agenT-797. Allogeneic iNKT cells are a novel immunotherapy approach that requires further testing.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating |
|---|---|---|---|---|
| Aug 15, 2025 | HC Wainwright & Co. | Upgrade | Neutral | Buy |
| Jul 15, 2025 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Jul 14, 2025 | William Blair | Downgrade | Outperform | Market Perform |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $8.8M · Total debt $0 · Total assets $9.6M · Shareholders' equity −$14.0M
- Revenue
- $0
- Operating income
- −$3.2M
- Net income
- −$3.1M
No dividends on record.
| Institutions23 holders · as of Mar 31, 2026 | 2.49% | 126.8K shares | |
| Insiders9 holders · as of Sep 2, 2026 | 4.09% | 208.7K shares | |
| Otherremainder | 93.42% | 4.77M shares |
5.10M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Vanguard Capital Management LLCInstitution | 1.16% | 59,364 | 13Fas of Mar 31, 2026 |
Jennifer BuellInsiderofficer: Chief Executive Officer | 1.14% | 57,942 | Form 4filed Jan 14, 2026 ↗ |
Brian CorveseInsiderdirector | 1.07% | 54,770 | Form 4filed Sep 2, 2026 ↗ |
Peter BehnerInsiderdirector | 0.48% | 24,404 | Form 4filed Sep 2, 2026 ↗ |
Ulf WiinbergInsiderdirector | 0.47% | 23,929 | Form 4filed Sep 2, 2026 ↗ |
| See all 25 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 4, 2026 | Barbara Ryan | director | −1,500 | $12.76 |
| Mar 10, 2026 | Barbara Ryan | director | −1,300 | $15.40 |
| Mar 9, 2026 | Barbara Ryan | director | −200 | $10.17 |
| Mar 2, 2026 | Barbara Ryan | director | −100 | $10.83 |
| Feb 27, 2026 | Barbara Ryan | director | −400 | $10.86 |
- Allogene Therapeutics
Allogeneic CAR T rival across oncology and autoimmune disease
- Adicet Bio
Allogeneic gamma delta T-cell rival in autoimmunity and cancer
- Century Therapeutics
iPSC-derived allogeneic cell-therapy rival in autoimmunity and cancer
- Nkarta
Off-the-shelf CAR-NK cell-therapy rival in autoimmune disease
- Artiva Biotherapeutics
Off-the-shelf NK cell-therapy rival in autoimmune disease
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| MiNK Therapeutics | $11.28 | +3.01% | $56.4M | — | — | — | — |
| Allogene Therapeutics | $1.99 | +0.42% | $683.4M | — | — | 147.3 | — |
| Adicet Bio | $9.34 | −0.21% | $86.6M | — | — | — | — |
| Century Therapeutics | $1.91 | −9.91% | $182.7M | — | — | — | — |
| Nkarta | $2.70 | −2.35% | $197.8M | — | — | — | — |
| Artiva Biotherapeutics | $11.34 | +0.53% | $552.9M | — | — | — | — |
| Median | — | — | 147.3 | — |